Catalyst Pharmaceuticals
Biopharmaceutical company focused on developing, commercializing, and supporting therapies for rare and difficult-to-treat neuromuscular and neurological diseases. Emphasizes patient advocacy, patient services, investigator-sponsored research support, in-licensing and product development, and has experience across analytical chemistry, manufacturing controls, quality systems, and regulatory processes.
Industries
Nr. of Employees
medium (51-250)
Catalyst Pharmaceuticals
Patents
Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
US-9254274-B2
View DetailsMethods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US-8969413-B2
View Details
Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
US-9254274-B2
View DetailsMethods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US-8969413-B2
View DetailsProducts
Commercial therapies for rare neuromuscular and neurological diseases
Marketed pharmaceutical therapies indicated for treatment of rare neuromuscular and neurological conditions; supported by development, regulatory, and patient service capabilities.
AGAMREE
AGAMREE is a corticosteroid with a novel structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
FIRDAPSE (amifampridine) Tablets 10 mg
The only FDA-approved treatment for people 6 years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS) that is clinically proven to maintain muscle strength and mobility.
FYCOMPA
FYCOMPA is a prescription medication used alone or in combination with other medicines to treat focal onset seizures and primary generalized tonic-clonic seizures in people with epilepsy.
Commercial therapies for rare neuromuscular and neurological diseases
Marketed pharmaceutical therapies indicated for treatment of rare neuromuscular and neurological conditions; supported by development, regulatory, and patient service capabilities.
AGAMREE
AGAMREE is a corticosteroid with a novel structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
FIRDAPSE (amifampridine) Tablets 10 mg
The only FDA-approved treatment for people 6 years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS) that is clinically proven to maintain muscle strength and mobility.
FYCOMPA
FYCOMPA is a prescription medication used alone or in combination with other medicines to treat focal onset seizures and primary generalized tonic-clonic seizures in people with epilepsy.
Services
Scientific and administrative evaluation of investigator-initiated studies; provision of funding and study drug when appropriate; alignment with product development priorities.
Personalized programs offering disease education, financial support options, patient navigation, and connections to advocacy resources.
Administration of targeted sponsorships and charitable grants to support research and patient community efforts.
Scientific and administrative evaluation of investigator-initiated studies; provision of funding and study drug when appropriate; alignment with product development priorities.
Personalized programs offering disease education, financial support options, patient navigation, and connections to advocacy resources.
Administration of targeted sponsorships and charitable grants to support research and patient community efforts.
Expertise Areas
- Rare disease drug development
- Clinical trial management and registries
- Patient advocacy and patient services
- Investigator-sponsored research support
Key Technologies
- Clinical registries
- Clinical trial management
- Analytical chemistry methods
- Chemistry, Manufacturing and Controls (CMC) processes
News & Updates
Public announcement and press release detailing completion of the acquisition of the company by Angelini Pharma.
Recap of a multi-day summit hosting university scholars to learn about patient advocacy and the role of patient engagement in drug development and commercialization.
Description of patient services team activities delivering handmade stuffed animals to pediatric patients as part of community engagement.
Company ranked on Forbes' 2026 list of America’s Most Successful Small-Cap Companies.
Public announcement and press release detailing completion of the acquisition of the company by Angelini Pharma.
Recap of a multi-day summit hosting university scholars to learn about patient advocacy and the role of patient engagement in drug development and commercialization.
Description of patient services team activities delivering handmade stuffed animals to pediatric patients as part of community engagement.
Company ranked on Forbes' 2026 list of America’s Most Successful Small-Cap Companies.